Trastuzumab (Herceptin) is a humanized monoclonal antibody that interferes with the HER2/neu receptor. Trastuzumab is used to treat certain breast cancers.

As a typical IgG1 antibody, Trastuzumab is comprised of a tetramer of two heavy and two light chains with one N-glycosylation site per heavy chain.

Protagen has experience in the analysis of different variants of Herceptin originators and biosimilars.

To support the analytical development of Herceptin biosimilars or biobetters, Protagen has set up an analysis program in accordance with ICH Q6B guidelines, including method setup, validation of customer-specific methods, and release testing. This package includes protein quantification, characterizing the protein primary structure, analysis of N- glycosylation and protein modifications.

Specific BioAssay provided by a strategic partner:

  • Target: HER2, ErbB2 Assay type: Proliferation Assay, statistical analysis by PLA



Your contact for Trastuzumab at Protagen Protein Services GmbH

Martin-Blueggel 150x100px

Martin Blüggel

Chief Executive Officer (CEO)
Our business development team will be happy to assist you with your project.

Phone: +49 (0) 231 9742-6100